BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10926083)

  • 1. Current concepts in androgen deprivation therapy--is there a "best" endocrine treatment?
    Gheiler EL; Tiguert R
    World J Urol; 2000 Jun; 18(3):190-3. PubMed ID: 10926083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The truth is out there: an overall perspective on androgen deprivation.
    Hellerstedt BA; Pienta KJ
    Urol Oncol; 2003; 21(4):272-81. PubMed ID: 12954498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in hormonal therapy for advanced prostate cancer.
    Oottamasathien S; Crawford ED
    Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arguments against the long-term use of combined androgen blockade.
    Studer UE; Mills RD
    Eur Urol; 1998; 34 Suppl 3():29-32. PubMed ID: 9854193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
    Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
    Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.
    Moul JW; Fowler JE
    Urology; 2003 Dec; 62(6 Suppl 1):20-8. PubMed ID: 14706505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for prostate cancer.
    Labrie F
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do we define "castration" in men on androgen deprivation therapy?
    Itty S; Getzenberg RH
    Asian J Androl; 2020; 22(5):441-446. PubMed ID: 31997782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
    Miller K
    Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
    Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
    BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional androgen ablation approaches to advanced prostate cancer: new insights.
    Rove KO; Crawford ED
    Can J Urol; 2014 Apr; 21(2 Supp 1):14-21. PubMed ID: 24775719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.